The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Self-citationNedd8 on cullin: building an expressway to protein destruction
Pan, Z.-Q., Kentsis, A., Dias, D. C., Yamoah, K., & Wu, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207414 · Cited by 429
Multimodal Activation of the Ubiquitin Ligase SCF by Nedd8 Conjugation
Saha, A., & Deshaies, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.08.021 · Cited by 396
A p53-Dependent Checkpoint Pathway Prevents Rereplication
Vaziri, C., Saxena, S., Jeon, Y., Lee, C., Murata, K., Machida, Y., Wagle, N., Hwang, D. S., & Dutta, A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00099-6 · Cited by 393
Two E3 ubiquitin ligases, SCF‐Skp2 and DDB1‐Cul4, target human Cdt1 for proteolysis
Nishitani, H., Sugimoto, N., Roukos, V., Nakanishi, Y., Saijo, M., Obuse, C., Tsurimoto, T., Nakayama, K. I., Nakayama, K., Fujita, M., et al. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601002 · Cited by 392
Nedd8 Modification of Cul-1 Activates SCFβTrCP-Dependent Ubiquitination of IκBα
Read, M. A., Brownell, J. E., Gladysheva, T. B., Hottelet, M., Parent, L. A., Coggins, M. B., Pierce, J. W., Podust, V. N., Luo, R.-S., Chau, V., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2326-2333.2000 · Cited by 363
Self-citationTargeted ubiquitination of CDT1 by the DDB1–CUL4A–ROC1 ligase in response to DNA damage
Hu, J., McCall, C. M., Ohta, T., & Xiong, Y. (2004) · Nature Cell Biology · doi:10.1038/ncb1172 · Cited by 348
Hershko, A. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401702 · Cited by 345
The Ubiquitin Ligase SCF Fbw7 Antagonizes Apoptotic JNK Signaling
Nateri, A. S., Riera-Sans, L., Costa, C. D., & Behrens, A. (2004) · Science · doi:10.1126/science.1092880 · Cited by 339
Margottin-Goguet, F., Hsu, J. Y., Loktev, A., Hsieh, H.-M., Reimann, J. D. R., & Jackson, P. K. (2003) · Developmental Cell · doi:10.1016/s1534-5807(03)00153-9 · Cited by 337
Bortezomib for the Treatment of Mantle Cell Lymphoma
Kane, R. C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0871 · Cited by 332
The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis.
Haas, A. L., & Rose, I. A. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34024-9 · Cited by 329
Right Place, Right Time, and Only Once: Replication Initiation in Metazoans
Machida, Y. J., Hamlin, J. L., & Dutta, A. (2005) · Cell · doi:10.1016/j.cell.2005.09.019 · Cited by 296
Radiation-mediated proteolysis of CDT1 by CUL4–ROC1 and CSN complexes constitutes a new checkpoint
Higa, L. A. A., Mihaylov, I. S., Banks, D. P., Zheng, J., & Zhang, H. (2003) · Nature Cell Biology · doi:10.1038/ncb1061 · Cited by 289
Walden, H., Podgorski, M. S., Huang, D. T., Miller, D. W., Howard, R. J., Minor, D. L., Holton, J. M., & Schulman, B. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00452-0 · Cited by 279
Identification of the Activating and Conjugating Enzymes of the NEDD8 Conjugation Pathway
Gong, L., & Yeh, E. T. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.12036 · Cited by 270
Loss of Geminin induces rereplication in the presence of functional p53
Melixetian, M., Ballabeni, A., Masiero, L., Gasparini, P., Zamponi, R., Bartek, J., Lukas, J., & Helin, K. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403106 · Cited by 262
A Nedd8 conjugation pathway is essential for proteolytic targeting of p27 Kip1 by ubiquitination
Podust, V. N., Brownell, J. E., Gladysheva, T. B., Luo, R.-S., Wang, C., Coggins, M. B., Pierce, J. W., Lightcap, E. S., & Chau, V. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090465597 · Cited by 244
Self-citationLi, X., Zhao, Q., Liao, R., Sun, P., & Wu, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300251200 · Cited by 244
Zhu, W., Chen, Y., & Dutta, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7140-7150.2004 · Cited by 222
Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8
Walden, H., Podgorski, M. S., & Schulman, B. A. (2003) · Nature · doi:10.1038/nature01456 · Cited by 217
Arias, E. E., & Walter, J. C. (2005) · Genes & Development · doi:10.1101/gad.1255805 · Cited by 196
Dual mode of degradation of Cdc25 A phosphatase
Donzelli, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf491 · Cited by 194
Chen, Y., McPhie, D. L., Hirschberg, J., & Neve, R. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8929 · Cited by 139
Recognition of Phosphodegron Motifs in Human Cyclin E by the SCFFbw7 Ubiquitin Ligase
Ye, X., Nalepa, G., Welcker, M., Kessler, B. M., Spooner, E., Qin, J., Elledge, S. J., Clurman, B. E., & Harper, J. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409226200 · Cited by 138
The discovery of ubiquitin-dependent proteolysis
Wilkinson, K. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504842102 · Cited by 128
Conservation in the Mechanism of Nedd8 Activation by the Human AppBp1-Uba3 Heterodimer*
Bohnsack, R., & Haas, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303177200 · Cited by 123
DDB1 Maintains Genome Integrity through Regulation of Cdt1
Lovejoy, C. A., Lock, K., Yenamandra, A. K., & Cortez, D. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00819-06 · Cited by 112
Disruption of Mechanisms That Prevent Rereplication Triggers a DNA Damage Response
Archambault, V., Ikui, A. E., Drapkin, B. J., & Cross, F. R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6707-6721.2005 · Cited by 91
Handeli, S., & Weintraub, H. M. (1992) · Cell · doi:10.1016/0092-8674(92)90594-3 · Cited by 87
Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system.
Chiba, T., & Tanaka, K. (2004) · Current protein and peptide science · doi:10.2174/1389203043379783 · Cited by 85
Rapid Degradation of Cdt1 upon UV-induced DNA Damage Is Mediated by SCF Complex
Kondo, T., Kobayashi, M., Tanaka, J., Yokoyama, A., Suzuki, S., Kato, N., Onozawa, M., Chiba, K., Hashino, S., Imamura, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314023200 · Cited by 85
Cdt1 degradation to prevent DNA re-replication: conserved and non-conserved pathways
Kim, Y., & Kipreos, E. T. (2007) · Cell Division · doi:10.1186/1747-1028-2-18 · Cited by 82
ATR Pathway Is the Primary Pathway for Activating G2/M Checkpoint Induction After Re-replication
Lin, J. J., & Dutta, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705178200 · Cited by 63
Inhibition of protein synthesis by 5'-sulfamoyladenosine
Bloch, A., & Coutsogeorgopoulos, C. (1971) · Biochemistry · doi:10.1021/bi00800a007 · Cited by 40
Geminin and p53: Deterrents to Re-replication in Human Cancer Cells
Saxena, S., & Dutta, A. (2003) · Cell Cycle · doi:10.4161/cc.2.4.443 · Cited by 18
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Acevedo Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1100356 · Cited by 5,894
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., Abeliovich, H., Abildgaard, M. H., Abudu, Y. P., Acevedo-Arozena, A., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1797280 · Cited by 2,897
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.